This company has been marked as potentially delisted and may not be actively trading. ERYTECH Pharma (ERYP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ERYP vs. IKT, PLX, IZTC, CRTX, ZIVO, CVM, JATT, CLDI, FNCH, and ALVRShould you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), CEL-SCI (CVM), JATT Acquisition (JATT), Calidi Biotherapeutics (CLDI), Finch Therapeutics Group (FNCH), and AlloVir (ALVR). These companies are all part of the "medical" sector. ERYTECH Pharma vs. Its Competitors Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies Cortexyme ZIVO Bioscience CEL-SCI JATT Acquisition Calidi Biotherapeutics Finch Therapeutics Group AlloVir ERYTECH Pharma (NASDAQ:ERYP) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends. Which has more volatility and risk, ERYP or IKT? ERYTECH Pharma has a beta of 2.69, suggesting that its stock price is 169% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Which has stronger earnings & valuation, ERYP or IKT? ERYTECH Pharma has higher revenue and earnings than Inhibikase Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioERYTECH Pharma$32.66M3.24-$240KN/AN/AInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.57 Does the media refer more to ERYP or IKT? In the previous week, Inhibikase Therapeutics had 1 more articles in the media than ERYTECH Pharma. MarketBeat recorded 1 mentions for Inhibikase Therapeutics and 0 mentions for ERYTECH Pharma. ERYTECH Pharma's average media sentiment score of 0.00 equaled Inhibikase Therapeutics'average media sentiment score. Company Overall Sentiment ERYTECH Pharma Neutral Inhibikase Therapeutics Neutral Is ERYP or IKT more profitable? ERYTECH Pharma's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ERYTECH PharmaN/A N/A N/A Inhibikase Therapeutics N/A -350.63%-201.82% Do institutionals and insiders have more ownership in ERYP or IKT? 1.1% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend ERYP or IKT? Inhibikase Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 327.63%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than ERYTECH Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ERYTECH Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryInhibikase Therapeutics beats ERYTECH Pharma on 6 of the 11 factors compared between the two stocks. Get ERYTECH Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERYP vs. The Competition Export to ExcelMetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.77M$277.00M$5.53B$9.36BDividend YieldN/AN/A4.74%4.14%P/E RatioN/AN/A28.9523.77Price / Sales3.24327.48443.4197.24Price / CashN/A22.4424.4827.20Price / Book3.8810.418.365.61Net Income-$240K-$106.40M$3.25B$265.26M ERYTECH Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERYPERYTECH PharmaN/A$3.10flatN/AN/A$105.77M$32.66M0.0049IKTInhibikase Therapeutics1.6674 of 5 stars$1.70-4.0%$6.50+282.4%+14.3%$126.38MN/A-0.646News CoveragePLXProtalix BioTherapeutics2.403 of 5 stars$1.46-2.7%$15.00+927.4%+38.1%$116.23M$59.76M-11.23200IZTCInvizyne TechnologiesN/A$9.98+0.3%N/AN/A$62.40MN/A0.0029Gap DownCRTXCortexymeN/A$1.85-0.5%N/A+140.0%$55.78MN/A-0.6255ZIVOZIVO BioscienceN/A$10.70-3.2%N/A+17.3%$40.84M$15.85K-2.1910CVMCEL-SCI1.1196 of 5 stars$7.15-17.0%N/A-72.6%$38.05MN/A-14.9043News CoveragePositive NewsShort Interest ↑High Trading VolumeJATTJATT AcquisitionN/A$1.64-2.4%N/A-58.8%$28.29MN/A0.003Gap DownHigh Trading VolumeCLDICalidi Biotherapeutics0.3005 of 5 stars$0.63+14.9%N/A-61.4%$22.94MN/A0.0038Short Interest ↑Gap DownHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+523.5%$20.08MN/A-1.42190ALVRAlloVirN/A$2.93+6.0%N/A-84.8%$14.75MN/A-0.14110Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies IKT Alternatives PLX Alternatives IZTC Alternatives CRTX Alternatives ZIVO Alternatives CVM Alternatives JATT Alternatives CLDI Alternatives FNCH Alternatives ALVR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERYP) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERYP Stock Alerts